United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $846,720.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $235.20, for a total transaction of $846,720.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,576. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Up 8.9 %

United Therapeutics stock opened at $255.14 on Thursday. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $261.54. The stock has a market cap of $12.01 billion, a PE ratio of 12.86 and a beta of 0.52. The firm’s 50-day simple moving average is $234.62 and its 200 day simple moving average is $228.81. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping the consensus estimate of $4.28 by $0.08. The business had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.67 earnings per share. Research analysts predict that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in United Therapeutics by 0.4% in the third quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company’s stock worth $1,053,212,000 after acquiring an additional 20,373 shares during the period. Dimensional Fund Advisors LP raised its position in shares of United Therapeutics by 1.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company’s stock valued at $123,566,000 after purchasing an additional 9,962 shares during the period. Norges Bank bought a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $100,519,000. LSV Asset Management raised its position in shares of United Therapeutics by 1.0% in the third quarter. LSV Asset Management now owns 383,068 shares of the biotechnology company’s stock valued at $86,524,000 after purchasing an additional 3,700 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of United Therapeutics by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 319,030 shares of the biotechnology company’s stock valued at $70,152,000 after purchasing an additional 7,723 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. SVB Leerink assumed coverage on shares of United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $294.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.